newsfilter
← Latest News
GlobeNewswire·

Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

- IVX-A12 is the first combination bivalent vaccine candidate against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to reach clinical stage - - Phase 1 topline interim results expected in mid-2023 - - Phase 2 initiatio